Recent investigations indicate that the combination of Loratinib and AMXT-1501 inhibits anaplastic lymphoma kinase (ALK), subsequently inhibiting SLC3A2 and thereby obstructing cell proliferation in neuroblastoma cell lines (91). The gene discussed is ALK; the disease is neuroblastoma.